GenesisM breaks ground on biomanufacturing facility in Bedford, Mass.

Rendering of GenesisM facility: ©Botanic Properties

GenesisM, a joint venture between Bain Capital Real Estate and Botanic Properties, broke ground on a 154,000-square-foot Class A biomanufacturing facility at 45 Crosby Drive in Bedford, Mass. The facility aims to address the growing demand for purpose-built life sciences manufacturing infrastructure in the Greater Boston area.

Local officials, project partners, and members of the biotech and real estate sectors attended the groundbreaking ceremony, which marks a significant milestone for the GenesisM platform and for Bedford's role in the life sciences industry.

“This groundbreaking marks a major milestone in the evolution of GenesisM,” said Joshua Zinns, managing principal of Botanic Properties. “We are proud to advance our mission of delivering flexible, capital-efficient biomanufacturing facilities that help companies bring innovative therapies to market faster and more efficiently. We are particularly pleased to be able to deliver this project in Bedford, Mass., which is one of the most forward-thinking communities for life science and technology companies.”

Strategically positioned along the Route 3 corridor and near Kendall Square’s thriving biotech ecosystem, the new facility is designed to house multiple tenants operating independently within highly regulated manufacturing suites. Each suite will feature dedicated infrastructure and systems tailored to stringent operational and compliance needs.

GenesisM’s “Enhanced Core” platform is a proprietary design concept that enables faster buildout timelines and lower capital costs for tenants. The Bedford facility will include 27-foot ceiling heights, up to 18 loading berths, 12,000 amps of power, and 40' x 40' column spacing—features that support long-term flexibility and scalability.

Construction is underway, with tenant fit-outs expected to begin as early as the second quarter of 2026 and final delivery of the core and shell scheduled for the third quarter of the same year.

Domestic biomanufacturing capacity: A strategic imperative

The GenesisM facility in Bedford arrives amid a broader national conversation about the importance of expanding domestic biomanufacturing capacity. The COVID-19 pandemic exposed vulnerabilities in global supply chains, particularly for pharmaceutical ingredients and biologic therapies. In response, both public and private sectors have accelerated efforts to bolster U.S.-based manufacturing for critical therapies and medical innovations.

Biomanufacturing, which includes the production of cell and gene therapies, monoclonal antibodies, and other biologics, requires specialized infrastructure that goes far beyond traditional commercial real estate. Clean rooms, GMP compliance, redundant utilities, and rigorous quality control systems are all essential components. However, the existing stock of suitable facilities in the United States—particularly in biotech hubs like Greater Boston—is limited.

Purpose-built developments like the one in Bedford are viewed as a key solution to this bottleneck. They provide companies with the ability to scale from clinical to commercial production without major capital outlays or delays. By reducing time to market and production risk, these facilities support both innovation and national resilience.

As the demand for advanced therapeutics continues to grow, so too does the strategic need for a robust domestic infrastructure capable of supporting it. The GenesisM project reflects not just a real estate investment, but a broader commitment to ensuring the U.S. remains a global leader in life sciences manufacturing.